D Chamil Codipilly1, Apoorva Krishna Chandar2, Kenneth K Wang1, David A Katzka1, John R Goldblum3, Prashanthi N Thota4, Gary W Falk5, Amitabh Chak6, Prasad G Iyer1. 1. Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. 2. Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. 3. Department of Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 4. Department of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 5. Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 6. Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA; Division of Gastroenterology and Liver Diseases, Case Western Reserve University, Cleveland, Ohio, USA.
Abstract
BACKGROUND AND AIMS: Seattle protocol forceps biopsy sampling (FB) is currently recommended for surveillance in Barrett's esophagus (BE) but limited by sampling error and lack of compliance. Wide-area transepithelial sampling with 3-dimensional analysis (WATS3D; CDx Diagnostics, Suffern, NY, USA) is reported to increase BE dysplasia detection. We assessed the incremental yield and clinical significance of WATS3D for dysplasia detection over FB in a systematic review and meta-analysis. METHODS: We queried major scientific databases for studies using WATS3D and FB from 2000 to 2020. The primary outcome was the incremental yield of WATS3D-detected dysplasia (defined as a composite of indefinite for dysplasia, low- and high-grade dysplasia [HGD] and esophageal adenocarcinoma [EAC]) over FB. Secondary outcomes were incremental yields of HGD/EAC and rate of reconfirmation of WATS3D dysplasia on subsequent FB. RESULTS: Meta-analysis of 7 eligible studies demonstrated that FB diagnosed dysplasia in 15.9% of cases, whereas the incremental yield with WATS3D was 7.2% (95% confidence interval, 3.9%-11.5%; I2= 92.1%). Meta-analysis of 6 studies demonstrated that FB diagnosed HGD/EAC in 2.3% of patients, whereas the incremental yield with WATS3D was 2.1% (95% confidence interval, .4%-5.3%; I2= 92.7%). Notably, WATS3D was negative in 62.5% of cases where FB identified dysplasia. Two studies reported reconfirmation of WATS3D dysplasia with FB histology in only 20 patients. CONCLUSIONS: WATS3D increases dysplasia detection; however, the clinical significance of this increased dysplasia detection remains uncertain. Data from endoscopic follow-up to ascertain FB histology in patients with dysplasia based solely on WATS3D are needed to determine the optimal clinical application and significance of WATS3D-only dysplasia.
BACKGROUND AND AIMS: Seattle protocol forceps biopsy sampling (FB) is currently recommended for surveillance in Barrett's esophagus (BE) but limited by sampling error and lack of compliance. Wide-area transepithelial sampling with 3-dimensional analysis (WATS3D; CDx Diagnostics, Suffern, NY, USA) is reported to increase BE dysplasia detection. We assessed the incremental yield and clinical significance of WATS3D for dysplasia detection over FB in a systematic review and meta-analysis. METHODS: We queried major scientific databases for studies using WATS3D and FB from 2000 to 2020. The primary outcome was the incremental yield of WATS3D-detected dysplasia (defined as a composite of indefinite for dysplasia, low- and high-grade dysplasia [HGD] and esophageal adenocarcinoma [EAC]) over FB. Secondary outcomes were incremental yields of HGD/EAC and rate of reconfirmation of WATS3D dysplasia on subsequent FB. RESULTS: Meta-analysis of 7 eligible studies demonstrated that FB diagnosed dysplasia in 15.9% of cases, whereas the incremental yield with WATS3D was 7.2% (95% confidence interval, 3.9%-11.5%; I2= 92.1%). Meta-analysis of 6 studies demonstrated that FB diagnosed HGD/EAC in 2.3% of patients, whereas the incremental yield with WATS3D was 2.1% (95% confidence interval, .4%-5.3%; I2= 92.7%). Notably, WATS3D was negative in 62.5% of cases where FB identified dysplasia. Two studies reported reconfirmation of WATS3D dysplasia with FB histology in only 20 patients. CONCLUSIONS: WATS3D increases dysplasia detection; however, the clinical significance of this increased dysplasia detection remains uncertain. Data from endoscopic follow-up to ascertain FB histology in patients with dysplasia based solely on WATS3D are needed to determine the optimal clinical application and significance of WATS3D-only dysplasia.
Authors: Cadman L Leggett; Jason T Lewis; Tsung Teh Wu; Cathy D Schleck; Alan R Zinsmeister; Kelly T Dunagan; Lori S Lutzke; Kenneth K Wang; Prasad G Iyer Journal: Clin Gastroenterol Hepatol Date: 2014-08-20 Impact factor: 11.382
Authors: Rajesh Krishnamoorthi; Babu P Mohan; Mahendran Jayaraj; Kenneth K Wang; David A Katzka; Andrew Ross; Douglas G Adler; Prasad G Iyer Journal: Gastrointest Endosc Date: 2019-08-14 Impact factor: 9.427
Authors: Nour Hamade; Sreekar Vennelaganti; Sravanthi Parasa; Prashanth Vennalaganti; Srinivas Gaddam; Manon C W Spaander; Sophie H van Olphen; Prashanthi N Thota; Kevin F Kennedy; Marco J Bruno; John J Vargo; Sharad Mathur; Brooks D Cash; Richard Sampliner; Neil Gupta; Gary W Falk; Ajay Bansal; Patrick E Young; David A Lieberman; Prateek Sharma Journal: Clin Gastroenterol Hepatol Date: 2018-08-08 Impact factor: 11.382
Authors: David A Katzka; Prasad G Iyer; Don C Codipilly; Tarek Sawas; Lovekirat Dhaliwal; Michele L Johnson; Ramona Lansing; Kenneth K Wang; Cadman L Leggett Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-12-11 Impact factor: 4.090
Authors: Shivaram K Bhat; Damian T McManus; Helen G Coleman; Brian T Johnston; Christopher R Cardwell; Una McMenamin; Finian Bannon; Blanaid Hicks; Grace Kennedy; Anna T Gavin; Liam J Murray Journal: Gut Date: 2014-04-03 Impact factor: 23.059
Authors: Hala Fatima; Maryiam Wajid; Nour Hamade; Yan Han; William Kessler; John Dewitt; Douglas Rex; Thomas Imperiale Journal: Ann Gastroenterol Date: 2022-01-07